References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492.
- Miszczyk M, Majewski W. Hematologic toxicity of conformal radiotherapy and intensity modulated radiotherapy in prostate and bladder cancer patients. Asian Pac J Cancer Prev. 2018;19(10): 2803–2806. doi:https://doi.org/10.22034/APJCP.2018.19.10.2803.
- Lewis S, Chopra S, Naga P, Pant S, Dandpani E, Bharadwaj N, et al. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin. Br J Radiol. 2018;91(1092):20180005. doi:https://doi.org/10.1259/bjr.20180005.
- Kumar T, Schernberg A, Busato F, Laurans M, Fumagalli I, Dumas I, et al. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. CMAR. 2019;11:6285–6297. doi:https://doi.org/10.2147/CMAR.S195989.
- Cho O, Chun M, Chang S-J, Oh Y-T, Noh OK. Prognostic value of severe lymphopenia during pelvic concurrent chemoradiotherapy in cervical cancer. Anticancer Res. 2016;36(7): 3541–3547.
- Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;140(1):76–82. doi:https://doi.org/10.1016/j.ygyno.2015.11.013.
- Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51. doi:https://doi.org/10.1016/j.critrevonc.2018.01.003.
- Mjaess G, Chebel R, Karam A, Moussa I, Pretot D, Abi Tayeh G, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses. Acta Oncol. 2021;15:1–10. doi:https://doi.org/10.1080/0284186X.2021.1886323.
- Blomgren H, Wasserman J, Littbrand B. Blood lymphocytes after radiation therapy of carcinoma of prostate and urinary bladder. Acta Radiol Ther Phys Biol. 1974;13(4):357–367. doi:https://doi.org/10.3109/02841867409134489.
- O’Toole C, Unsgaard B. Clinical status and rate of recovery of blood lymphocyte levels after radiotherapy for bladder cancer. Cancer Res. 1979;39(3):840–843.
- Elsworthy M, Plowman PN. Peripheral blood lymphocyte counts during standard conformal radiotherapy and TomoTherapy/IMRT for prostate cancer. J Radiother Pract. 2008;7(4):223–227. doi:https://doi.org/10.1017/S1460396908006444.
- Razzaghdoust A, Mozdarani H, Mofid B, Aghamiri SMR, Heidari AH. Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer. Prostate. 2014;74(1):41–47. doi:https://doi.org/10.1002/pros.22725.
- Cozzarini C, Noris Chiorda B, Sini C, Fiorino C, Briganti A, Montorsi F, et al. Hematologic toxicity in patients treated with postprostatectomy whole-pelvis irradiation with different intensity modulated radiation therapy techniques is not negligible and is prolonged: preliminary results of a longitudinal, observational study. Int J Radiat Oncol Biol Phys. 2016;95(2):690–695. doi:https://doi.org/10.1016/j.ijrobp.2016.01.022.
- Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;118(1):79–84. doi:https://doi.org/10.1016/j.radonc.2015.11.020.
- Mondino A, Lazarević D, Fiorino C, et al. EP-1230: the level of lymphopenia inversely correlates with the risk for late urinary toxicity after WPRTfor prostate cancer. Radiother Oncol. 2015;115.
- Antunac K, Suton P, Bilić-Knežević S. Prognostic significance of radiation induced lymphopenia in patients with high risk prostate cancer. Libri Oncol: Croatian J Oncol. 2019;46(2–3):55–59.
- Schad MD, Dutta SW, Muller DM, Wijesooriya K, Showalter TN. Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer. Adv Radiat Oncol. 2019;4(2):323–330. doi:https://doi.org/10.1016/j.adro.2019.01.005.
- Wang Y, Dong X, Qu Z, Peng K, Sun X, Chen R, et al. Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer. BMC Cancer. 2020;20(1):900. doi:https://doi.org/10.1186/s12885-020-07382-3.
- Elumalai T, Aversa C, Buijtenhuijs B, Conroy R, Croxford W, Das A, et al. 765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data. Ann Oncol. 2020;31:S590. doi:https://doi.org/10.1016/j.annonc.2020.08.837.
- Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:https://doi.org/10.1101/gad.314617.118.
- Tharmalingam H, Choudhury A, Van Herk M, McWilliam A, Hoskin PJ. New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nat Rev Urol. 2019;16(9):523–538. doi:https://doi.org/10.1038/s41585-019-0213-3.
- Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. JCO. 2021;39(11):1234–1242. doi:https://doi.org/10.1200/JCO.20.03282.